MA49753A - Agents de liaison se liant à pd-l1 et cd137 et leur utilisation - Google Patents

Agents de liaison se liant à pd-l1 et cd137 et leur utilisation

Info

Publication number
MA49753A
MA49753A MA049753A MA49753A MA49753A MA 49753 A MA49753 A MA 49753A MA 049753 A MA049753 A MA 049753A MA 49753 A MA49753 A MA 49753A MA 49753 A MA49753 A MA 49753A
Authority
MA
Morocco
Prior art keywords
liners
Prior art date
Application number
MA049753A
Other languages
English (en)
Inventor
Isil Altintas
Friederike Gieseke
Christian Grunwitz
Alexander Muik
Paul Parren
Rik Rademaker
Ugur Sahin
David Satijn
Original Assignee
BioNTech SE
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE, Genmab As filed Critical BioNTech SE
Publication of MA49753A publication Critical patent/MA49753A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA049753A 2017-08-04 2018-08-02 Agents de liaison se liant à pd-l1 et cd137 et leur utilisation MA49753A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017069839 2017-08-04
EP2018052946 2018-02-06

Publications (1)

Publication Number Publication Date
MA49753A true MA49753A (fr) 2020-06-10

Family

ID=63244552

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049753A MA49753A (fr) 2017-08-04 2018-08-02 Agents de liaison se liant à pd-l1 et cd137 et leur utilisation

Country Status (15)

Country Link
US (5) US10968280B2 (fr)
EP (1) EP3661960A1 (fr)
JP (2) JP7290013B2 (fr)
KR (1) KR20200064062A (fr)
CN (2) CN111406067B (fr)
AU (1) AU2018309339A1 (fr)
BR (1) BR112020001944A2 (fr)
CA (1) CA3071211A1 (fr)
IL (1) IL272159A (fr)
MA (1) MA49753A (fr)
MX (1) MX2020001198A (fr)
NZ (1) NZ761294A (fr)
SA (1) SA520411173B1 (fr)
SG (1) SG11202000198QA (fr)
WO (1) WO2019025545A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018142573A (ru) 2016-06-20 2020-07-21 Ф-Стар Бета Лимитед Партнеры по связыванию lag-3
AU2017283181B2 (en) 2016-06-20 2024-08-15 F-Star Therapeutics Limited Binding molecules binding PD-L1 and LAG-3
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CN110325209A (zh) 2017-02-24 2019-10-11 宏观基因有限公司 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
CA3055127A1 (fr) * 2017-03-09 2018-09-13 Genmab A/S Anticorps diriges contre pd-l1
EP3596108A4 (fr) 2017-03-15 2020-12-23 Pandion Operations, Inc. Immunotolérance ciblée
BR112019024127A2 (pt) 2017-05-24 2020-06-23 Pandion Therapeutics, Inc. Imunotolerância alvejada
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CA3086098A1 (fr) 2017-12-19 2019-06-27 F-Star Beta Limited Sequences de liaison specifiques a pd-l1 inserees dans un domaine ch3
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
MX2021000398A (es) 2018-07-12 2021-05-27 F Star Therapeutics Ltd Moleculas de anticuerpo que se unen a pd-l1 y cd137.
EP3972992A4 (fr) 2019-05-20 2023-07-19 Pandion Operations, Inc. Immunotolérance ciblée madcam
WO2021013142A1 (fr) * 2019-07-22 2021-01-28 江苏恒瑞医药股份有限公司 Anticorps anti-4-1bb, fragment de liaison à l'antigène de celui-ci et anticorps bispécifique
US11466086B2 (en) 2019-10-11 2022-10-11 Nanjing Leads Biolabs Co., Ltd. Antibodies binding 4-1BB and uses thereof
MX2022009091A (es) 2020-02-04 2022-09-19 Genmab As Anticuerpos para usarse en terapia.
WO2021155916A1 (fr) * 2020-02-04 2021-08-12 BioNTech SE Traitement impliquant une vaccination d'antigène et des agents de liaison se liant à pd-l1 et cd137
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CN114195900B (zh) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
AU2021350473A1 (en) * 2020-09-28 2023-04-27 Merus N.V. Method for detecting expression or clustering of cell surface moieties
CN112430271B (zh) * 2020-11-13 2021-09-03 武汉滨会生物科技股份有限公司 一种双特异性单链抗体及应用
CN117083080A (zh) 2020-12-07 2023-11-17 健玛保 抗体和紫杉烷联合疗法
AU2021398976A1 (en) * 2020-12-16 2023-07-06 Merus N.V. Multispecific antibodies for the treatment of cancer
MX2023008172A (es) * 2021-01-08 2023-07-18 Beijing Hanmi Pharmaceutical Co Ltd Anticuerpo biespecifico de forma heterodimerica similar a la estructura del anticuerpo natural anti-pd-l1/anti-4-1bb y preparacion del mismo.
JP2024521701A (ja) * 2021-05-21 2024-06-04 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｃｄ１３７抗体及びその使用方法
BR112023027006A2 (pt) 2021-06-21 2024-03-12 BioNTech SE Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação
IL311771A (en) 2021-10-06 2024-05-01 BioNTech SE Multispecific binding agents against PD-L1 and CD137 in combination
AU2022360108A1 (en) 2021-10-06 2024-05-02 BioNTech SE Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers
AR127298A1 (es) 2021-10-08 2024-01-10 Genmab As Anticuerpos que se unen a cd30 y cd3
WO2023174521A1 (fr) * 2022-03-15 2023-09-21 Genmab A/S Agents de liaison se liant à epcam et cd137
WO2024040212A2 (fr) * 2022-08-19 2024-02-22 Staidson Biopharma Inc. Anticorps reconnaissant spécifiquement le ligand 1 de mort cellulaire programmée 1 et utilisations associées
WO2024209072A1 (fr) 2023-04-06 2024-10-10 Genmab A/S Agents de liaison multispécifiques dirigés contre pd-l1 et cd137 pour le traitement du cancer

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1992022653A1 (fr) 1991-06-14 1992-12-23 Genentech, Inc. Procede de production d'anticorps humanises
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
CA2361421A1 (fr) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Particules therapeutiques de phosphate de calcium et procedes de fabrication et d'utilisation associes
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
AU2003209446B2 (en) 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
DE10161767T1 (de) 2002-07-03 2018-06-07 Honjo Tasuku Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten
CA2965865C (fr) 2002-07-18 2021-10-19 Merus N.V. Production par recombinaison de melanges d'anticorps
AU2004255216B2 (en) 2003-07-01 2010-08-19 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP3050963B1 (fr) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007059782A1 (fr) 2005-11-28 2007-05-31 Genmab A/S Anticorps monovalents recombines et leurs procedes de production
JP5374359B2 (ja) 2006-03-17 2013-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定化されたポリペプチド化合物
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2626372B1 (fr) 2007-03-29 2018-03-21 Genmab A/S Anticorps bispécifiques et procédés de production de ceux-ci
CN101821288A (zh) 2007-06-21 2010-09-01 宏观基因有限公司 共价双抗体及其用途
PL2201100T3 (pl) 2007-09-14 2016-10-31 Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniu
EP2195341B1 (fr) 2007-09-26 2017-03-22 UCB Biopharma SPRL Fusions d'anticorps à double spécificité
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
WO2010015792A1 (fr) 2008-08-06 2010-02-11 Argenta Discovery Limited Composés hétérocycliques contenant de l'azote utiles comme modulateurs bifonctionnels des récepteurs m3 et des récepteurs bêta-2
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
CA2998281C (fr) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Anticorps anti-pd-1 humains et leurs utilisations
KR20110112301A (ko) 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
KR20110104032A (ko) 2008-12-19 2011-09-21 마크로제닉스, 인크. 공유결합형 디아바디 및 이의 용도
CN102448984A (zh) 2009-03-27 2012-05-09 酶遗传学股份有限公司 使用包含抗体-受体组合的多特异性结合蛋白的组合物和方法
EP2424567B1 (fr) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
DK3279215T3 (da) 2009-11-24 2020-04-27 Medimmune Ltd Målrettede bindemidler mod b7-h1
CN102711810B (zh) 2009-11-30 2015-04-22 詹森生物科技公司 效应子功能已消除的抗体Fc区突变体
RU2580038C2 (ru) 2009-12-04 2016-04-10 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
DK2542590T4 (da) 2010-03-05 2020-07-13 Univ Johns Hopkins Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
JP6022444B2 (ja) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
MX338953B (es) 2010-08-16 2016-05-06 Novimmune Sa Metodos para la generacion de anticuerpos multiespecificos y multivalentes.
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
MX340558B (es) 2010-08-24 2016-07-14 F Hoffmann-La Roche Ag * Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
EP3674320A3 (fr) 2011-10-27 2020-08-12 Genmab A/S Production de proteines heterodimeres
SI2785375T1 (sl) 2011-11-28 2020-11-30 Merck Patent Gmbh Protitelesa proti PD-L1 in uporabe le-teh
AU2013249985B2 (en) 2012-04-20 2017-11-23 Merus N.V. Methods and means for the production of Ig-like molecules
AU2013255542C1 (en) 2012-04-30 2017-06-22 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
SG11201407190TA (en) 2012-05-15 2014-12-30 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
JP6403166B2 (ja) 2012-08-03 2018-10-10 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 単一抗原抗ｐｄ−ｌ１およびｐｄ−ｌ２二重結合抗体およびその使用方法
CN104870476B (zh) 2012-11-21 2018-04-13 药物抗体公司 靶向vegfr‑2和dll4的双靶向抗体及包含它的药物组合物
RS58627B2 (sr) 2014-04-01 2022-06-30 Biontech Cell&Gene Therapies Gmbh Klaudin-6-specifični imuno receptori i t-ćelijski epitopi
CA2943943C (fr) 2014-04-07 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Molecule d'immunoactivation de liaison a un antigene
EP3233907B1 (fr) 2014-12-19 2021-03-03 Genmab A/S Protéines hétérodimères bispécifiques de rongeurs
WO2016100882A1 (fr) 2014-12-19 2016-06-23 Novartis Ag Polythérapies
JP6853176B2 (ja) * 2015-01-08 2021-03-31 ゲンマブ エー／エス Ｃｄ３およびｃｄ２０に対する二重特異性抗体
DK3623386T3 (da) 2015-01-08 2022-07-04 BioNTech SE Agonistiske tnf-receptor-bindingsmidler
CN107921104A (zh) * 2015-02-22 2018-04-17 索伦托治疗有限公司 结合cd137的抗体疗法
PE20181349A1 (es) 2015-10-07 2018-08-22 Hoffmann La Roche Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
CA3009661A1 (fr) * 2016-01-11 2017-07-20 Inhibrx, Inc. Proteines de fusion se liant a gitr multivalentes et multispecifiques
MX2018012897A (es) 2016-04-22 2019-01-17 Alligator Bioscience Ab Nuevos polipeptidos biespecificos contra cd137.
WO2017201281A1 (fr) 2016-05-18 2017-11-23 Mayo Foundation For Medical Education And Research Ciblage de pd-l1 sur des cellules tumorales
WO2017205738A1 (fr) 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Protéines de liaison bispécifiques se liant à une protéine immunomodulatrice et à un antigène tumoral
SG10201913326UA (en) 2016-06-07 2020-02-27 Macrogenics Inc Combination therapy
CA3026151A1 (fr) 2016-06-14 2017-12-21 Xencor, Inc. Anticorps inhibiteurs de points de controle bispecifiques
BR112019000512A2 (pt) * 2016-07-14 2019-04-24 Genmab A/S anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
WO2018014260A1 (fr) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Protéines de liaison antigènes multi-spécifiques et leurs procédés d'utilisation
US20190338040A1 (en) 2016-07-20 2019-11-07 Igm Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof
CN109983033B (zh) 2016-09-23 2023-10-31 美勒斯公司 调节细胞表达的生物活性的结合分子
CA3055127A1 (fr) * 2017-03-09 2018-09-13 Genmab A/S Anticorps diriges contre pd-l1
WO2018213747A1 (fr) 2017-05-19 2018-11-22 Merrimack Pharmaceuticals, Inc. Molécules bispécifiques agonistes de 4-1bb et de cd40

Also Published As

Publication number Publication date
AU2018309339A1 (en) 2020-02-20
US20210269541A1 (en) 2021-09-02
US20230087745A1 (en) 2023-03-23
MX2020001198A (es) 2020-09-07
CN116333131A (zh) 2023-06-27
CN111406067B (zh) 2022-11-08
SA520411173B1 (ar) 2023-12-13
SG11202000198QA (en) 2020-02-27
EP3661960A1 (fr) 2020-06-10
US11459395B2 (en) 2022-10-04
US20210277133A1 (en) 2021-09-09
JP2020529438A (ja) 2020-10-08
BR112020001944A2 (pt) 2020-08-04
US20210163616A1 (en) 2021-06-03
JP2023100942A (ja) 2023-07-19
CN111406067A (zh) 2020-07-10
JP7290013B2 (ja) 2023-06-13
US10968280B2 (en) 2021-04-06
IL272159A (en) 2020-03-31
US20200165349A1 (en) 2020-05-28
WO2019025545A1 (fr) 2019-02-07
KR20200064062A (ko) 2020-06-05
NZ761294A (en) 2024-05-31
CA3071211A1 (fr) 2019-02-07

Similar Documents

Publication Publication Date Title
MA49753A (fr) Agents de liaison se liant à pd-l1 et cd137 et leur utilisation
EP3706845A4 (fr) Système de support de décision clinique pour la détection et la gestion d'une asynchronie entre le patient et le ventilateur
FR24C1033I1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
MA44225A (fr) Sulfonylurées et composés apparentés et leur utilisation
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA44776A (fr) Anticorps anti-vista humain et leur utilisation
MA43364A (fr) Composés d'alcènes tétrasubstitués et leur utilisation
MA47440A (fr) Sulfonylurées, composés apparentés, et leur utilisation
MA41414A (fr) Protéines de liaison agonistes d' icos
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
MA43260A (fr) Liants pd1 et/ou lag3
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA44993A (fr) Polypeptides de fusion cd40l-fc et procédés d'utilisation associés
BR112018000834A2 (pt) compósito de elastômero reforçado com sílica e produtos contendo o mesmo
MA45613A (fr) Composés polycycliques-carbamoylpyridones et leur utilisation pharmaceutique
MA52285A (fr) Anticorps multispécifiques et leur utilisation
MA40721A (fr) Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
MA45709A (fr) Composés diazahétérobicycliques substitués et leur utilisation
BR112016025910A2 (pt) uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos
MA50404A (fr) Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées
MA56183A (fr) Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b
MA46059A (fr) Variants de l'endonucléase homing tim3, compositions et procédés d'utilisation
MA41296A (fr) Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
MA51224A (fr) Composés de sulfonamide et leur utilisation